Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announcement for quarter ended September 30, 2026.
ABEONA THERAPEUTICS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announcement for quarter ended September 30, 2026
- Press release issued November 9, 2026, with results and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Investor presentation disseminated November 9, 2026, providing updated corporate and pipeline information
- Exhibit 99.2 contains the presentation, the primary source for details on programs, milestones and strategy
Item EX-99.1 · Exhibit EX-99.1
- Q3 ZEVASKYN revenue $13.5M, up 18% sequentially, confirming early commercial traction
- 15 treatments completed since launch, with six in Q3 and eight QTC sites activated
- NTAP reimbursement effective October 1, supporting hospital adoption for eligible Medicare patients representing approximately 10% of RDEB patients
- ABO-801 acquired as a Phase 3-ready EoE asset, with $20M stock issued, potential $30M FDA milestone, and up to $30M sales milestones
- Cash $134.9M at September 30, with $30M PIPE financing announced after quarter-end; Q3 net loss $4.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ABEONA THERAPEUTICS INC. 8-K filings
Get the next ABEO 8-K as it lands
Follow ABEO for push alerts, or ask the research agent what this filing means.